The worldwide incidence of Chronic Kidney Disease (CKD) has reached epidemic proportions and is a major health care burden. A key medical challenge is to provide new therapeutic tools to tackle CKD progression. We think our research has the potential to establish another pathway as a valid drug target in this area. The rationale for this contention is based on our preliminary data implicating this new signalling axis as having a fundamental role in CKD progression. We found that this pathological pathway was 1) active before the first signs of kidney dysfunction could be detected in humans and mice, 2) an active player in disease progression, 3) a potential urinary biomarker in the diagnosis of CKD progression. Indeed we showed that by knocking it down in CKD mouse models, we blocked the progression of the disease. The project aims to substantiate this hypothesis and thereby pave the way towards the identification of novel biomarkers and therapeutic targets of CKD.
Monsieur Christos CHATZIANTONIOU (Maladies Rénales Fréquentes et Rares: des mécanismes moléculaires à la Médecine personnalisée)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
University College London UCL Great Ormond Street-Institute of Child Health / Developmental Biology and cancer
INSERM UMRS 1151 INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
U1155 Maladies Rénales Fréquentes et Rares: des mécanismes moléculaires à la Médecine personnalisée
Help of the ANR 468,120 euros
Beginning and duration of the scientific project:
September 2019
- 36 Months
